Skip to main content
Premium Trial:

Request an Annual Quote

Marina Completes Enrollment of First Cohort in FAP Drug Trial

Premium

Marina Biotech said this week that it has completed enrollment of the first cohort in a phase I study of its RNAi-based treatment for its familial adenomatous polyposis treatment CEQ508.

The drug uses orally delivered attenuated Escherichia coli to transcribe shRNAs targeting beta-catenin, an oncogene that plays a role in the development of colorectal polyps that characterize the disease. The company began the clinical trial last month (GSN 3/17/2011).

"We're into our second week of drug administration with our first patient and anticipate dosing the subsequent two patients in this group in the coming weeks,” Daniel Chung, a clinician at Massachusetts General Hospital and the phase I trial's principal investigator, said in a statement.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.